Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:35:30.566Z.
Calculation as of: 2026-10-06T20:35:30.566Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d9de0dbfadb283a207fe687abae4d6c7414f83280ed3d33a9edf26fe3e5e7dd3
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$828.48M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$833.81M
PE Ratio
N/A
TTM Avg
76.88
3Y Avg
76.88
5Y Avg
76.88
Market Cap
$838.62M
PE Ratio
N/A
TTM Avg
351.06
3Y Avg
351.06
5Y Avg
351.06
Market Cap
$789.34M
PE Ratio
N/A
TTM Avg
694.69
3Y Avg
438.87
5Y Avg
438.87
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ardelyx, Inc. (ARDX) | $817.67M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $816.13M | N/A | N/A | N/A | N/A |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $828.48M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $804.16M | 11.37 | 9.51 | 9.54 | 15.29 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | N/A | 76.88 | 76.88 | 76.88 |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | 351.06 | 351.06 | 351.06 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $789.34M | N/A | 694.69 | 438.87 | 438.87 |
| AdaptHealth Corp. (AHCO)vs › | $785.03M | N/A | 16.88 | 41.08 | 41.08 |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$3.31
Forward EPS (Est.)
$-0.18
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2015-11-12 | 189.54 |
| 2015-11-11 | 201.67 |
| 2015-11-10 | 201.26 |
| 2015-11-09 | 200.00 |
| 2015-11-06 | 200.00 |
| 2015-11-05 | 188.28 |
| 2015-11-04 | 190.79 |
| 2015-11-03 | 183.68 |
| 2015-11-02 | 181.17 |
| 2015-10-30 | 171.55 |
| 2015-10-29 | 176.99 |
| 2015-10-28 | 182.85 |
| 2015-10-27 | 171.55 |
| 2015-10-26 | 179.92 |
| 2015-10-23 | 165.69 |
| 2015-10-22 | 177.82 |
| 2015-10-21 | 179.92 |
| 2015-10-20 | 193.72 |
| 2015-10-19 | 201.67 |
| 2015-10-16 | 202.93 |
| 2015-10-15 | 203.35 |
| 2015-10-14 | 194.98 |
| 2015-10-13 | 210.46 |
| 2015-10-12 | 214.64 |
| 2015-10-09 | 216.74 |
| 2015-10-08 | 209.62 |
| 2015-10-07 | 210.04 |
| 2015-10-06 | 193.72 |
| 2015-10-05 | 192.89 |
| 2015-10-02 | 194.98 |
| 2015-10-01 | 175.73 |
| 2015-09-30 | 180.75 |
| 2015-09-29 | 174.06 |
| 2015-09-28 | 184.94 |
| 2015-09-25 | 210.04 |
| 2015-09-24 | 226.36 |
| 2015-09-23 | 222.59 |
| 2015-09-22 | 223.85 |
| 2015-09-21 | 221.34 |
| 2015-09-18 | 230.13 |
| 2015-09-17 | 224.69 |
| 2015-09-16 | 218.83 |
| 2015-09-15 | 223.01 |
| 2015-09-14 | 223.01 |
| 2015-09-11 | 217.99 |
| 2015-09-10 | 215.90 |
| 2015-09-09 | 207.95 |
| 2015-09-08 | 214.23 |
| 2015-09-04 | 197.49 |
| 2015-09-03 | 194.14 |
| 2015-09-02 | 200.84 |
| 2015-09-01 | 196.23 |
| 2015-08-31 | 198.74 |
| 2015-08-28 | 196.23 |
| 2015-08-27 | 184.52 |
| 2015-08-26 | 185.36 |
| 2015-08-25 | 179.08 |
| 2015-08-24 | 174.90 |
| 2015-08-21 | 182.01 |
| 2015-08-20 | 180.75 |
| 2015-08-19 | 190.38 |
| 2015-08-18 | 202.51 |
| 2015-08-17 | 197.49 |
| 2015-08-14 | 197.91 |
| 2015-08-13 | 190.38 |
